Uterine Fibroids are the abnormal growth that gets developed inside or on the wall of a woman's uterus. These are also known as leiomyoma or myomas. The U.S. Uterine Fibroids Market is expected to reach USD 39,993.2 million by the end of the forecasted period and is expected to grow at a CAGR of 3.24%.
Uterine fibroids are the noncancerous growths of the uterus, which mostly appear during childbearing years. It is the abnormal growth of that gets developed inside or on the wall of a woman's uterus. Uterine fibroids is also known as myomas or leiomyomas. The symptom of uterine fibroids are frequent urination, constipation, backache, heavy menstrual bleeding, pelvic pressure, or menstrual periods lasting more than a week. The women with mild symptoms may go for medical treatments such as hormonal drugs, gonadotropin agonists, progestin and oral contraceptives. Women with moderate to severe symptoms may need surgery to treat uterine fibroids. According to the U.S. Department of Health and Human Services office on Women Health, about 20% to 80% of women develop fibroids by the age of 50 and nearly 30% will get them at the age of 35. Uterine fibroids are most common in women in their 40s and early 50s.
U.S. Uterine Fibroid Market – Key Players
Some of the key players in this market are:
-- AstraZeneca (England)
-- Cook Medical Inc. (US)
-- Boston Scientific Corporation (US)
-- GE Healthcare (U.K.)
-- AbbVie Inc. (U.S.)
-- Hologic (U.S.)
U.S. Uterine Fibroid Market – Study Objectives
-- To provide detailed analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the U.S. Uterine Fibroid Market
-- To provide insights about factors affecting the market growth
-- To analyze the market based on various factors – price analysis, supply chain analysis, porters five force analysis etc.
-- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
U.S. Uterine Fibroid Market – Regional Analysis
The market of Uterine Fibroid devices is much higher in the United States region, owing to its high prevalence in African- American race, change in lifestyle. According to one large cohort study of NIS on African-American women in Maryland, uterine fibroids was the cause of 65.4% of total 53,000 women undergoing hysterectomy.
Moreover, most of the major market players belong from this region, thus they introduce the advance technology firstly in the United States in comparison to others region. Additionally the market players of this region also involve in export of Uterine Fibroid devices in the developing regions of Asia Pacific for meeting the unmet needs. Also Government of developing countries are willing to adopt advanced treatment option available in developed countries, in order to improve the quality of life of their citizen, which fuel the market of Uterine Fibroid devices. Countries like India and China are more focused market for United States market players owing to the huge patient population and growing purchasing power as compare to other countries in this region. Thus the players belong from the United States have opportunity of increase the market share and maximize the profit by exporting to these nation.
U.S. Uterine Fibroid Market – Competitive Analysis
Increasing incidence of uterine fibroid United States generate the interest of companies toward the market of uterine fibroid, as they feel there are huge opportunities and gaps between the market demand and supply of quality devices. Thus, companies are showing more interest in research and development activities for introducing the advanced treatment that meets the requirement of market. For instant, in Feb 2017, AstraZeneca has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. Moreover, in Nov 2016, Boston Scientific Corporation Acquires Resectr Tissue Resection Device from Distal Access, LLC. The portfolio includes the Resectr Tissue Resection Device, a single-use solution designed to effectively remove uterine polyps. The companies are introducing better devices for getting the leadership in the Uterine Fibroid devices market. Additionally company are focusing more into research and development activity in order to launch advanced device for the treatment of uterine fibroid. In this regard, GE today announced the launch of the Optima MR430s, a new specialty scanner with breakthrough technology that delivers precise imaging with exceptional comfort and the 1.5T image quality radiologists require. These invention help company to lead the market of uterine fibroid in United States.
U.S. Uterine Fibroid Market - Segments
U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners, Computed tomography (CT), Ultrasounds and others. On the basis of treatment the market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.
Read More @ https://www.marketresearchfuture.com/reports/uterine-fibroid-market-2394
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.